Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Autologous iPSC-derived Dopaminergic Progenitor Cell Transplantation for Parkinson's Disease
NCT06687837Phase 1Recruiting
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in Parkinson's disease (PD) (2 arms). Primary endpoint: Safety and Tolerability at 2 years. Started Apr 2025; status: recruiting.
02
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06687837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06687837.